gbt021601
Small moleculeexperimental
Clinical trial activity
8 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
0
Phase 3
2
Phase 4
0
Earliest trial started Dec 9, 2020 (NCT05036512)
Timeline
Indications
Mechanism of action
- Hemoglobin HbASupplementation
HBB supplementation
Chemistry & pharmacology
Loading structure…
SMILES
O=Cc1c(O)cccc1OC[C@@H]1COCCN1C(=O)c1cccnc1CCO- Mol. weight
- 386.4 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314424 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06507904 | Phase 1 | Mar 31, 2025 | Pfizer |
| NCT06340347 | Phase 1 | Apr 30, 2024 | Pfizer |
| NCT05878704 | Phase 1 | Jun 29, 2023 | Pfizer |
| NCT05632354 | Phase 2/Phase 3 (Phase 3) | Jan 3, 2023 | Global Blood Therapeutics, Inc. |
| NCT05718687 | Phase 1 | Dec 22, 2022 | Pfizer |
| NCT05431088 | Phase 2/Phase 3 (Phase 3) | Oct 10, 2022 | Global Blood Therapeutics, Inc. |
| NCT04983264 | Phase 1 | May 28, 2021 | Global Blood Therapeutics, Inc. |
| NCT05036512 | Phase 1 | Dec 9, 2020 | Global Blood Therapeutics, Inc. |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Global Blood Therapeutics, Inc. | For profit | 4 | 4 | 2 | 2020 |
| Pfizer | For profit | 4 | 4 | 1 | 2022 |
2 organizations
Page 1 / 1